[Concurrent treatment of osteoporosis including vitamin K].
The 2006 version of the guideline for prophylaxis and treatment of osteoporosis recommends vitamin K(VK)supplementation in the state of its deficiency. As VK(2) gained grade B in all aspects in the guideline, single use of the drug is limited. VK(2) may be used concurrently with other drugs in the treatment of osteoporosis. In this paper, the results of our concurrent use of two of vitamin D(3), VK(2), and EHDP are summarized, and the combined therapy including VK(2) will be reviewed.
Kobayashi
Seneki
S
Shinshu University School of Medicine, Department of Orthopaedic Surgery.
Shiraki
Masataka
M
Takaoka
Kunio
K
D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000008:administration & dosage; D002762:Cholecalciferol / Q000008:administration & dosage; D004164:Diphosphonates / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D015914:Estrogen Replacement Therapy; D012968:Etidronic Acid / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D015337:Multicenter Studies as Topic; D010024:Osteoporosis / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D016103:Spinal Fractures / Q000209:etiology / Q000517:prevention & control; D024482:Vitamin K 2 / Q000008:administration & dosage*
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D024482:Vitamin K 2; D002762:Cholecalciferol; D012968:Etidronic Acid